Wednesday, November 11, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 2, 2026

SK Telecom CEO Unveils 'AI Native' Strategy at MWC26, Driving Korea's Leap in AI Innovation

View original at finance.yahoo.com
SK Telecom CEO Unveils 'AI Native' Strategy at MWC26, Driving Korea's Leap in AI Innovation - Seizing the golden time for a major transformation, with 'Customer Value & AI' as the top two priorities for driving change - Major overhaul of systems and infrastructure, the foundation of telecommunications, centered on AI -…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • To drive future growth, we must reinvent our way of working from the ground up. SKT will fundamentally transform its corporate culture to be centered around AI

    80% confidence

  • SKT is currently at a golden time of transformation, where the two tasks of customer value innovation and AI innovation intersect in a borderless, converged environment that goes beyond telecommunications

    80% confidence

  • AIDC can be seen as the heart of Korea, and hyperscale LLMs as the brain. By combining SKT's AI capabilities with collaboration from domestic and global partners, we will lead true AI-native transformation for Korean customers and enterprises

    80% confidence

  • By implementing company-wide AI upskilling education and campaigns, we will transform our organizational culture to be AI Native. Through SKT's new transformation, we will do our utmost to regain the trust of our customers and become a company that contributes to the nation and society

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
SK Telecom CEO Unveils 'AI Native' Strategy at MWC26, Driving Korea's Leap in AI Innovation — Source | Via News | Via News